O., Podgaec, S., Dias Jr, J
Furthermore, the incidence of grade 3 or higher TRAEs was 25.6% among those who received dato-DXd vs 42.1% in patients who received paclitaxel in TROPION-Lung01
Back to Journals Journal of Hepatocellular Carcinoma Volume 12 Natural Bioactive Compounds Targeting the Wnt/-Catenin Pathway for the Treatment of Hepatocellular Carcinoma Authors Tian H, Wang P, Shao H Received 19 February 2025 Accepted for publication 11 July 2025 Published 23 July 2025 Volume 2025:12 Pages 16131622 DOI Checked for plagiarism Yes Review by Single anonymous peer review Peer reviewer comments 2 Editor who approved publication: Dr Ali Hosni Haoyu Tian, Peng Wang, Haibo Shao Department of Interventional Radiology, The First Hospital of China Medical University, Shenyang, Liaoning, Peoples Republic of China Correspondence: Haibo Shao, Department of Interventional Radiology, The First Hospital of China Medical University, Shenyang, Peoples Republic of China, Email [email protected] Abstract: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide, with limited treatment options and poor prognosis
This is because stress affects the permeability of the gastrointestinal wall, which can create a leaky gut
long-term epidemiological data absent Metabolic effects potential impacts on glucose metabolism, insulin sensitivity, and lipid profiles inadequately characterized in long-term studies Endocrine disruption effects on other hormonal axes with chronic use not well-studied Regulatory & Competitive Sport Status FDA Position Neither CJC-1295 nor Ipamorelin has received FDA approval for any human therapeutic indication: Investigational New Drug status available only for qualified research applications 2024 FDA compounding restrictions both peptides temporarily placed on Category 2 list (substances presenting significant safety risks), later removed pending further review Not approved for human use in any formulation or indication Warning letters issued to companies marketing peptides for human therapeutic use Compounding status uncertain as of 2024-2025, regulatory position on compounding pharmacy access remains in flux The FDA has specifically cited cardiovascular safety concerns, immunogenicity risks, and lack of adequate safety and efficacy data as bases for restricting access outside formal research contexts
